CStone Suzhou Translational Medicine Research Center (TMRC) is a cutting edge clinical research institution built according to international standards. The primary goal of the center is to accelerate clinical development through the discovery and validation of predictive biomarkers, in order to bring the right therapies to the right patients in China. With the establishment of the Suzhou TMRC, CStone has solidified its global strategic roadmap. We expect to have several Class I innovative anti-cancer drugs at different phases of clinical development by 2020.
Leverage (reverse) translational biomarker research to augment success rate of clinical development, enrich pipeline, discover new combination strategies and targets
Promote interdisciplinary collaboration with domestic and international companies and institutions
Cultivate China's innovative talents in collaboration with local academic institutions
Pre-clinical Preclinical Discoveries Validate Resistance Mechanism Clinical Use preclinical discoveries to guide patient selection and monitor treatment response in clinical trials; use clinical findings to guide preclinical discovery of drug resistance mechanisms.
Increase the success rate of clinical trials by three times 26% With Biomarkers 8% Without Biomarkers Facilitate the development of precision medicine by accurate prediction of treatment response.
Your privacy is important for us. We use cookies to enhance your experience when visiting our websites: performance cookies show us how you use this website, functional cookies remember your preferences and targeting cookies help us to share content relevant to you. Select “Accept all” for giving your consent to all cookies or select “Reject all” for using only strictly necessary cookies.
